

This is a repository copy of *Prospective cohort study of the predictive value of inflammatory biomarkers over clinical variables in children and young people with cancer presenting with fever and neutropenia.*

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/185127/>

Version: Published Version

---

**Article:**

Phillips, Bob [orcid.org/0000-0002-4938-9673](https://orcid.org/0000-0002-4938-9673) (2022) Prospective cohort study of the predictive value of inflammatory biomarkers over clinical variables in children and young people with cancer presenting with fever and neutropenia. F1000research. 1070. ISSN 2046-1402

<https://doi.org/10.12688/f1000research.73075.1>

---

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



## BRIEF REPORT

# REVISED Prospective cohort study of the predictive value of inflammatory biomarkers over clinical variables in children and young people with cancer presenting with fever and neutropenia [version 2; peer review: 2 approved]

Bob Phillips <sup>1,2</sup>

<sup>1</sup>Centre for Reviews and Dissemination, University of York, York, Yorkshire, YO10 5DD, UK

<sup>2</sup>Regional Department of Paediatric Haematology and Oncology, Leeds Teaching Hospitals NHS Trust, Leeds, LS1 9TX, UK

**V2** First published: 22 Oct 2021, 10:1070  
<https://doi.org/10.12688/f1000research.73075.1>  
 Latest published: 03 Feb 2022, 10:1070  
<https://doi.org/10.12688/f1000research.73075.2>

## Abstract

### Introduction

Fever during chemotherapy induced neutropenia is a common and potentially life-threatening complication of the treatment of childhood cancer. Predictions of poor outcome could be enhanced by incorporating serum biomarkers of inflammation at presentation and reassessment.

### Methods

A prospective cohort study was conducted of children under 18 years old, being treated for cancer or a cancer-like condition, who presented with fever ( $\geq 38.0^{\circ}\text{C}$ ) and neutropenia (neutrophil count  $< 0.5 \times 10^9/\text{L}$ ). Clinical features were recorded, along with three experimental inflammatory biomarkers: procalcitonin (PCT), interleukin-6 (IL-6) and interleukin-8 (IL-8). Outcomes included serious medical complications (SMC): any infection related mortality, critical care and organ support, severe sepsis, septic shock, significant microbiologically defined infection, or radiologically confirmed pneumonia.

### Results

Biomarker assessments were undertaken in 43 episodes of fever and neutropenia, from 31 patients aged between four months and 17 years old (median six years): 20 were female and 22 had acute leukaemia. Five episodes of SMC were noted. PCT, IL-6 and IL-8 had poor individual discriminatory ability (C-statistic 0.48 to 0.60) and did not add to the value of clinical risk stratification tools. Insufficient data were collected to formally assess the value of repeated assessments.

### Conclusions

Incorporating serum biomarkers of inflammation at presentation of episodes of fever with neutropenia in childhood does not clearly improve risk stratification. The value of serial assessments requires further investigation.

## Open Peer Review

Approval Status

	1	2
<b>version 2</b>		
(revision)		
03 Feb 2022		
<b>version 1</b>		
22 Oct 2021		


1. **Paul J. Gibson** , McMaster University, Hamilton, Canada

2. **Rejin Kebudi** , Oncology Institute, Istanbul University, Istanbul, Turkey


Any reports and responses or comments on the article can be found at the end of the article.

**Keywords**

febrile neutropenia, neutropenic sepsis, childhood cancer, inflammatory biomarkers, IL6, IL8, procalcitonin



This article is included in the **Oncology** gateway.



This article is included in the **Multicancer early detection and screening** collection.

**Corresponding author:** Bob Phillips ([bob.phillips@york.ac.uk](mailto:bob.phillips@york.ac.uk))

**Author roles: Phillips B:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

**Competing interests:** No competing interests were disclosed.

**Grant information:** Dr Phillips (Post-Doctoral Research Fellow, PDF10872) was funded by the National Institute for Health Research (NIHR) for this research project. The views expressed in this paper are those of the author and not necessarily those of the NIHR, NHS or the UK Department of Health and Social Care.

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Copyright:** © 2022 Phillips B. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Phillips B. **Prospective cohort study of the predictive value of inflammatory biomarkers over clinical variables in children and young people with cancer presenting with fever and neutropenia [version 2; peer review: 2 approved]** F1000Research 2022, 10:1070 <https://doi.org/10.12688/f1000research.73075.2>

**First published:** 22 Oct 2021, 10:1070 <https://doi.org/10.12688/f1000research.73075.1>

**REVISED Amendments from Version 1**

This version is in response to two peer reviewers' comments. The abstract final line has been modified to say "The value of serial assessments requires further investigation" which softens the tone. An extra paragraph is added to the discussion, exploring the reasons for the small numbers of patient episodes captured, and the range of the biomarkers as well as mean values have been added to Table 3.

**Any further responses from the reviewers can be found at the end of the article**

**Introduction**

Infection, frequently presenting as fever during chemotherapy induced neutropenia, is a common and potentially life-threatening complication of the treatment of childhood cancer. Modern management approaches have promoted the use of clinical decision rules to stratify patients at low risk of serious medical complications during febrile neutropenia (FN), enabling them to be safely managed with less intensive therapy as an outpatient.<sup>1</sup>

In addition to the role of clinical risk stratification, there is an increased desire to use modern biochemical markers of inflammation in predicting the risk of severe sepsis. There is increasing interest in inflammatory biomarkers such as procalcitonin (PCT), an inflammatory marker that has been shown to rise in response to bacterial infection in non-immunosuppressed children,<sup>2</sup> and various cytokines including interleukin (IL)-6 and IL-8 to improve the diagnostic accuracy of a prediction rule in children with FN.<sup>3</sup>

A systematic review and meta-analysis of the discriminatory ability of biomarkers in children with FN<sup>4,5</sup> concluded that while several small studies suggest PCT, IL-6 and IL-8 may be valuable for predicting severe infection in children with FN, the true impact remains unknown. The lack of value of older biomarkers, such as C-reactive protein (CRP), is confirmed in these reviews. A smaller number of studies explored the role of serial (i.e., 0 h, 12–24 h, 48 h) biomarkers to detect documented infection or sepsis. In one study, the difference between CRP, PCT and IL-8 at 24 hours in children with and without sepsis was more pronounced than at presentation.<sup>6</sup> These data suggest the optimal value for prediction may be made by incorporating biomarkers at early reassessment (i.e., within 12–24 h or 24–48 h), rather than at presentation.

This study aimed to undertake a focused analysis of three promising inflammatory biomarkers: PCT, IL-6 and IL-8 in both initial and value of serial testing and their additional discriminatory value above routine clinical features using the PICNICC model<sup>7</sup> and AUS-score.<sup>8</sup>

**Methods**

This study took place in Leeds Children's Hospital between March 2016 and March 2018. It recruited patients on presentation of FN or pre-enrolled them during routine appointments where they, or their parents or guardians, affirmed their consent in written form. In addition to formal information sheets, a link to an animated video summary of the research was provided <https://www.youtube.com/watch?v=Z1AXzJqatds>.<sup>9</sup> Ethical approval was given by the Leeds West NHS Research Ethics Committee [15/YH/0357].

Children could be included who were: younger than 18 years old, who had cancer, or received a stem cell transplant, or who had Langerhans cell histiocytosis in need of cytotoxic chemotherapy, or haemophagocytic lymphohistiocytosis undergoing active treatment, or severe aplastic anaemia, and attended with febrile neutropenia. Fever was defined as temperature  $\geq 38.0^{\circ}\text{C}$  and neutropenia, an absolute neutrophil count  $\leq 0.5$  g/L.

All patients were admitted to hospital and managed according to institutional FN pathways; these consisted of full evaluation and empiric piperacillin/tazobactam (or suitable alternatives) until afebrile 48 hours and with no other reason for antimicrobials, regardless of neutrophil count. Inflammatory biomarkers, with the exception of CRP, were analysed in batches and their results masked from the treating team. Using this unselective approach, with treatment unaffected by the results of the biomarker analyses, we minimized the biases which can arise through cherry-picking of patients and altering medical treatment on the basis of the test under evaluation (selection and incorporation biases).

Demographic data, variables and outcomes included core items as devised by the International Paediatric Fever in Neutropenia Working Group (see Extended Data, Table 1)<sup>9</sup>. Clinical assessments and blood samples for biomarkers were taken at presentation (within 12 h of fever or admission) and daily until the end of the FN episode or discharge as part of usual clinical care.

**Table 1. Distribution of diagnosis in 31 patients with biomarker data.**


Diagnosis	Number of patients
Acute leukaemias	21
Other haematological malignancies	2
Solid tumours	5
Brain tumours	3

The primary outcome measure was ‘serious medical complication (SMC)’<sup>10</sup> (defined by any of (i) infection related mortality (ii) admission to ICU/HDU/other ward/unit for organ support (iii) severe sepsis or (iv) septic shock) or significant microbiologically defined infection, or radiologically confirmed pneumonia. Secondary outcomes measures were the component parts of the primary outcome, death within 30 days, infection related mortality, clinically defined infection, infection with antibiotic-resistant bacteria and relapse of primary infection. Initial power calculations estimated ~400 episodes would detect an additional benefit C-statistic discriminatory of +0.10.

Results were analysed descriptively, and assessment made of the individual discriminatory value of the inflammatory biomarkers using the C-statistic for SMC, and their additional value to clinical prediction rules (PICNICC prediction and AUS-score). Analyses were undertaken using base R version 3.6.0 (R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria) (RRID:SCR\_001905) and the package pROC (pROC: an open-source package for R and S+ to analyze and compare ROC curves) Further analysis of the results was planned to be by hierarchical logistic regression modelling of episodes within patients, assessing the predictive value of clinical and then biomarkers of inflammation at admission, day one and subsequent timepoints. Additional assessments of the sensitivity and specificity of the markers, alone and in combination, were also proposed.

**Results**

Data was collected from 65 patients with an episode of fever and neutropenia. Of those, 43 episodes in 31 patients had biomarker samples taken, with 31 episodes with ‘day one’ data. The distribution of diagnoses is shown in Table 1. The patients ranged from four months to 17 years old (median six years), and 20 were female.



**Figure 1. Plots of discriminatory values of admission biomarkers in distinguishing patients with serious medical complication (SMC).** CRP = C-reactive protein; PCT = procalcitonin; IL-6 = interleukin-6; IL-8 = interleukin-8.

**Table 2. C-statistic values for biomarkers to distinguish patients with serious medical complication (SMC).** CRP = C-reactive protein; PCT = procalcitonin; IL-6 = interleukin-6; IL-8 = interleukin-8.

Biomarker		With PICNICC prediction	With AUS-score
CRP	0.60	0.69	0.71
PCT	0.54	0.55	0.59
IL-6	0.57	0.55	0.57
IL-8	0.48	0.64	0.58
Rule alone		0.65	0.53

**Table 3. Mean biomarker levels in patients who did, and did not, appear clinically unwell at presentation.** CRP = C-reactive protein; PCT = procalcitonin; IL-6 = interleukin-6; IL-8 = interleukin-8.

Biomarker	Mean (range) 'severe' clinical appearance (n = 5)	Mean (range) 'non-severe' clinical appearance (n = -26)
CRP	111 mg/dL (5 – 213)	42 mg/dL (3 – 155)
PCT	5.8 ng/ml (<0.05 – 29.2)	0.03 ng/ml (<0.05 – 3.6)
IL-6	105 pg/ml (11.8 – 216)	67 pg/ml (1 – 296)
IL-8	210 pg/ml (40.9 – 514)	176 pg/ml (5 – 718)

Of these 31 episodes, five were assigned an SMC: two significant viral infections with oxygen requirement, and one each of: *Fusobacterium* blood stream infection, *Escherichia coli* urinary tract infection, and culture-negative severe sepsis requiring fluid boluses. No patient received intensive care support or died. There were eight non-serious viral infections and one non-serious central line colonization.

All biomarkers performed poorly in distinguishing those who developed an SMC (see Figure 1), with C-statistic estimates ranging from 0.48 to 0.60 (see Table 2). The biomarkers were ineffective in improving the discriminatory value of the PICNICC risk prediction (change in C-statistic:  $-0.10$  to  $+0.04$ ), and only marginally useful in improving the simpler AUS-score ( $+0.04$  to  $+0.18$ ) (See Extended Data, Table 2)<sup>9</sup> Given the paucity of data and lack of diagnostic value, no complex analyses were undertaken.

The biomarker levels concurred better with the physician assessment of “severe” clinical illness, though in no case was this statistically significantly different (see Table 3,  $p > 0.10$ ).

Repeated measures of the biomarkers were available in 25 episodes. Development of SMC did not occur in patients who presented with non-severe symptoms and consistently low inflammatory biomarkers despite ongoing fevers. Of those with SMC, 4/5 had reductions in biomarker levels as their infection resolved; they stayed high in the one case of culture negative severe sepsis.

## Discussion

This prospective study of inflammatory biomarkers in paediatric febrile neutropenia found little support for their use as indicators of covert infection. Technical and administrative challenges limited the number of samples collected during the study, despite enthusiasm from the patients and their families. This adds to the body of evidence describing a relatively limited role in initial stratification.

Serial use of these markers, where they can be used to suggest an infection is under control, or controlled, is an area of active testing. PCT has been studied in several patient groups to diagnose sepsis and monitor response to treatment. A systematic review<sup>11</sup> and subsequent large (>1500 patients) RCT with pragmatic study design examining PCT-guided decision-making in neonates (NeoPIs) with suspected infection and critically ill adults on ICU (SAPS) found significant reductions in antibiotic duration in the PCT arm.<sup>12,13</sup> Two large UK studies looking at the same question in adults and children with suspected or proven serious bacterial infections are ongoing.<sup>14,15</sup> These studies specifically exclude immunocompromised patients such as children with cancer, and work exploring this is required to enhance patient experience and reduce antimicrobial resistance.<sup>16–18</sup>

The challenges in taking samples consistently over time during acute admissions, often after the ‘working hours’ of the research team, were considerable. In-patients, particularly in the stem cell transplant ward, had blood samples drawn consistently. In other areas the initial sample was often missed, and subsequently no more taken during that episode. The ward teams remembering to request daily additional samples was an unsurmounted barrier. Electronic order sets, now widespread in healthcare, were not present during this study and a subsequent pilot study using PCT had greater sample collection success. Extending the time for the study to run was not possible.

The results of this study should dissuade clinicians from routinely using inflammatory biomarkers in making initial stratification of children with febrile neutropenia. The onward investigation of their serial use in antimicrobial stewardship should be pursued within carefully monitored studies.

## Data availability

### Underlying data

The data for this study contains the following elements, which when combined would make the patients identifiable given the rarity of childhood cancer in the identified geographical area and time of this study:

Demographic data: (ii) episode date; (iii) age; (iv) cancer diagnosis & treatment.

FN episode data: (i) inpatient or outpatient onset; (ii) time of start of temperature; (iii) time of presentation.

A reduced dataset taking out all items to produce sufficient anonymity (for sensitive data; childhood cancer) would severely limit their utility for researchers.

The patients and families who took part in this study, and the Research Ethics Committee who granted permission for it, agreed the data should be available for sharing in ethically approved secondary use projects. Such studies are typically individual participant data meta-analysis collaboratives. Anyone who has such an approved project, investigating aspects of paediatric febrile neutropenia and biomarker profiles, is encouraged to approach the author at [bob.phillips@york.ac.uk](mailto:bob.phillips@york.ac.uk) for access to the dataset.

### Extended data

Open Science Framework (OSF): Extended data for ‘Prospective cohort study of the predictive value of inflammatory biomarkers over clinical variables in children and young people with cancer presenting with fever and neutropenia’, <https://www.doi.org/10.17605/OSF.IO/CVFZB>.<sup>9</sup>

This project contains the following extended data:

- Extended Data Tables.docx (Extended **Table 1**: Data items collected and Extended **Table 2**: AUC-ROC (C-statistic) values for biomarkers to distinguish patients with SMC)
- Consent Video (mp4 format)

Data are available under the terms of the [Creative Commons Zero “No rights reserved” data waiver](#) (CC0 1.0 Public domain dedication).

## Consent

Written informed consent for publication of the patients’ details was obtained from the patients/parents/guardian of the patient.

## References

1. Klastersky J, Paesmans M, Rubenstein EB, *et al.*: **The Multinational Association for Supportive Care in Cancer risk index**. *J. Clin. Oncol.* 2000; **18**(16): 3038–51.  
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Irwin AD, Carrol ED: **Procalcitonin**. *Arch. Dis. Child. Educ. Pract. Ed.* 2011; **96**(6): 228–33.  
[PubMed Abstract](#) | [Publisher Full Text](#)
3. Haeusler GM, Slavin MA: **Complications of sepsis: the role of risk prediction rules, biomarkers and host genetics**. *Expert Rev. Anti. Ther.* 2012; **10**(7): 733–5.  
[PubMed Abstract](#) | [Publisher Full Text](#)
4. Phillips RS, Wade R, Lehrnbecher T, *et al.*: **Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic**

- episodes in children and young people with cancer. *BMC Med.* 2012; **10**: 6.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
5. Haeusler GM, Carlesse F, Phillips RS: **An Updated Systematic Review and Meta-Analysis of the Predictive Value of Serum Biomarkers in the Assessment of Fever during Neutropenia in Children with Cancer.** *Pediatr. Infect. Dis. J.* 2013; **32**(10): e390–6. [published Online First: 2013/05/16].  
[PubMed Abstract](#) | [Publisher Full Text](#)
  6. Santolaya ME, Alvarez AM, Aviles CL, *et al.*: **Predictors of severe sepsis not clinically apparent during the first twenty-four hours of hospitalization in children with cancer, neutropenia, and fever: a prospective, multicenter trial.** *Pediatr. Infect. Dis. J.* 2008; **27**(6): 538–43.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  7. Phillips RS, Sung L, Ammann RA, *et al.*: **Predicting microbiologically defined infection in febrile neutropenic episodes in children: global individual participant data multivariable meta-analysis.** *Br. J. Cancer.* 2016; **114**(12): e17. [published Online First: 2016/05/27].  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  8. Phillips B, Morgan JE: **Meta-analytic validation of new 'AUS' febrile neutropenia risk score.** *Pediatr. Blood Cancer.* 2021; **68**(1): e28580. [published Online First: 2020/07/28].  
[PubMed Abstract](#) | [Publisher Full Text](#)
  9. Phillips B: **NIHR-PDF Biomarkers.** *OSF.* 2021.  
[Publisher Full Text](#)
  10. Goldstein B, Giroir B, Randolph A, *et al.*: **International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics.** *Pediatr. Crit. Care Med.* 2005; **6**(1): 2–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  11. Westwood M, Ramaekers B, Whiting P, *et al.*: **Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis.** *Health Technol. Assess. (Winch. Eng.).* 2015; **19**(96): 1–236. [published Online First: 2015/11/17].  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  12. Stocker M, van Herk W, El Helou S, *et al.*: **Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns).** *Lancet (London, Eng.).* 2017; **390**(10097): 871–81. [published Online First: 2017/07/18].  
[PubMed Abstract](#) | [Publisher Full Text](#)
  13. de Jong E, van Oers JA, Beishuizen A, *et al.*: **Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial.** *Lancet Infect. Dis.* 2016; **16**(7): 819–27. [published Online First: 2016/03/08].  
[PubMed Abstract](#) | [Publisher Full Text](#)
  14. ADAPT-Sepsis: Biomarker-guided duration of antibiotic treatment for sepsis: **ISRCTN47473244.**
  15. Biomarker-guided duration of Antibiotic Treatment in Children Hospitalised with confirmed or suspected bacterial infection (The BATCH Trial): **ISRCTN 11369832.**
  16. Public Health England: **Start Smart - Then Focus: Antimicrobial Stewardship Toolkit for English Hospitals.** *PHE Publications Gateway 2014828.* March 2015.
  17. National Institute for Health and Care Excellence: **Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay); Diagnostics guidance [DG18].** 2015.
  18. National Institute for Health and Care Excellence: **Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use (NG15).** *NICE Guidance.* 2015.



# Open Peer Review

Current Peer Review Status:  

---

## Version 2

Reviewer Report 10 February 2022

<https://doi.org/10.5256/f1000research.120929.r122269>

© 2022 Gibson P. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Paul J. Gibson** 

Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada

Thanks to the author for his work and his edits in response to the review. No further suggestions.

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** I am a clinical pediatric oncologist with research experience in supportive care. I cannot however, confidently suggest all statistical methods quoted in the paper are appropriate.

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Reviewer Report 07 February 2022

<https://doi.org/10.5256/f1000research.120929.r122270>

© 2022 Kebudi R. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Rejin Kebudi** 

Division of Pediatric Hematology-Oncology, Oncology Institute, Istanbul University, Istanbul, Turkey

The paper is very valuable in its revised form.

Approved.

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Pediatric oncology

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

---

Version 1

Reviewer Report 21 January 2022

<https://doi.org/10.5256/f1000research.76698.r100188>

© 2022 Kebudi R. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Rejin Kebudi** 

Division of Pediatric Hematology-Oncology, Oncology Institute, Istanbul University, Istanbul, Turkey

The manuscript *Prospective cohort study of the predictive value of inflammatory biomarkers over clinical variables in children and young people with cancer presenting with fever and neutropenia* investigates the role of PCT, IL6, IL8 at first day and serial monitoring in paediatric febrile neutropenic episodes.

The unselective approach for the biomarkers (the inflammatory biomarker results except for CRP were masked from the treating team) minimized the biases for medical treatment. Did the results of CRP (which the medical team could see) effect treatment decisions?

There were 43 episodes and 31 patients, only 31 episodes had first day data. Despite that, the biomarker levels concurred better with the physician assessment of severe clinical illness, however, this was not statistically significant. The conclusion was that at presentation of febrile neutropenic episodes, serum biomarkers of inflammation do not improve the risk stratification, repeated assessment over time may be of value.

Were there any differences in patients who had acute leukemia vs solid tumors? Were all of the febrile neutropenic episodes, in which biomarkers were investigated, high risk? If there were both high risk and low risk episodes, did the biomarkers differ within the risk groups?

In table 3 the mean inflammatory biomarker values in severe clinical appearance are numerically much higher than the non-severe ones; what was the range of each biomarker in the severe and non-severe group. Do the authors define the severe clinical appearance (table 3) the same as SMC?

Although the use of these biomarkers were not statistically significant in initial stratification, the evaluation of a larger cohort with higher number of SMC, may give more information on the value of the initial inflammatory biomarkers for predicting a SMC or sepsis. A larger cohort may also give more information for the value of the use of serial biomarker monitoring and which one/ones to use cost-effectively. The discussion may include some of these concerns.

Do see this for further reference. <sup>1</sup>

### References

1. Lehrnbecher T, Phillips R, Alexander S, Alvaro F, et al.: Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. *J Clin Oncol*. 2012; **30** (35): 4427-38 [PubMed Abstract](#) | [Publisher Full Text](#)

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

Yes

**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Pediatric oncology

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Author Response ( ) 01 Feb 2022

**Bob Phillips**, University of York, UK, York, UK

There are a number of interesting questions raised in the review:

1. Were there any differences in patients who had acute leukemia vs solid tumors?

**This is a very fair question, and no, there were no qualitative differences in patient type. Given the small numbers, multiple analyses for variation were felt to be unwise and only the highest level (risk-grouping and biomarkers) were undertaken.**

1. Were all of the febrile neutropenic episodes, in which biomarkers were investigated, high risk? If there were both high risk and low risk episodes, did the biomarkers differ within the risk groups?

**The risk groups are shown in Extended Data Table 2; they included all levels of risk.**

1. In table 3 the mean inflammatory biomarker values in severe clinical appearance are numerically much higher than the non-severe ones; what was the range of each biomarker in the severe and non-severe group.

**This is a good question and Table 3 has been modified to add the (range) as well as the mean values.**

1. Do the authors define the severe clinical appearance (table 3) the same as SMC?

**No - severe clinical appearance and significant medical complication are defined differently. SMC is defined in the fifth methods paragraph, "severe clinical appearance" is the gestalt impression of the examining physician.**

**Competing Interests:** Author of the manuscript

Reviewer Report 10 November 2021

<https://doi.org/10.5256/f1000research.76698.r97615>

© 2021 Gibson P. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Paul J. Gibson** 

Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada

### **General Comments:**

This is a nice small study that tackles an interesting and still unanswered question with regards to the utility of biomarkers in the risk stratification of Pediatric Febrile Neutropenia. However, it appears there were challenges in recruitment and sample collection that are not specifically outlined. It may be helpful to describe those challenges to guide future efforts.

### **Abstract:**

Conclusions: "Repeated assessments over time may be of value". I'm not convinced that the body of the paper nor the discussion justify this statement based on the results of this study. While other studies are referenced that may point to the utility of serial assessments, the concept is not substantially discussed in this paper.

### **Introduction:**

The second paragraph mentions interest in newer biomarkers but fails to address CRP until it used as a single example in the 3rd paragraph. I suggest the authors make earlier reference to this

'older' biomarker and its role (or lack thereof) in risk stratification and highlight why PCT IL-6 and IL-8 may be preferable.

### **Methods:**

"Using this unselective approach, with treatment unaffected by the results of the biomarker analyses, we minimized the biases which can arise through cherry-picking of patients and altering medical treatment on the basis of the test under evaluation (selection and incorporation biases)". This sentence may be more succinctly stated. such as "PCT, IL-6 and IL-8 values were not provided to clinicians to avoid bias"

As Table 1 states results, it is more appropriate in the results section.

The methods reference power calculations suggesting ~400 episodes were required. but only 43 were captured, yet there is no explanation for planned duration or reason for termination of the study.

### **Results**

Data was collected on 65 patients, yet only 31 have had biomarkers taken? Why? Did they refuse collection? Did they present outside of times feasible for biomarker collection? The Discussion references technical and administrative challenges, but maybe expand what you mean?

You may consider showing graphically the changes in biomarkers in the 5 SMC patients.

### **Is the work clearly and accurately presented and does it cite the current literature?**

Yes

### **Is the study design appropriate and is the work technically sound?**

Yes

### **Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

### **If applicable, is the statistical analysis and its interpretation appropriate?**

I cannot comment. A qualified statistician is required.

### **Are all the source data underlying the results available to ensure full reproducibility?**

Partly

### **Are the conclusions drawn adequately supported by the results?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** I am a clinical pediatric oncologist with research experience in supportive care. I cannot however, confidently suggest all statistical methods quoted in the paper are

appropriate.

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.**

Author Response ( ) 01 Feb 2022

**Bob Phillips**, University of York, UK, York, UK

"General Comments:

1. This is a nice small study that tackles an interesting and still unanswered question with regards to the utility of biomarkers in the risk stratification of Pediatric Febrile Neutropenia. However, it appears there were challenges in recruitment and sample collection that are not specifically outlined. It may be helpful to describe those challenges to guide future efforts."

**This is an extremely good point, and paragraph 3 has been added to the Discussion.**

"Abstract:

1. Conclusions: "Repeated assessments over time may be of value". I'm not convinced that the body of the paper nor the discussion justify this statement based on the results of this study. While other studies are referenced that may point to the utility of serial assessments, the concept is not substantially discussed in this paper."

**This is also reasonable – the few data there are congruent but an overstatement from this report. Modified.**

"Introduction:

1. The second paragraph mentions interest in newer biomarkers but fails to address CRP until it used as a single example in the 3rd paragraph. I suggest the authors make earlier reference to this 'older' biomarker and its role (or lack thereof) in risk stratification and highlight why PCT IL-6 and IL-8 may be preferable. "

**A worthwhile negative to explicitly state. Added to into paragraph 3 to explain why the newer ones are possibly better.**

"Methods:

1. "Using this unselective approach, with treatment unaffected by the results of the biomarker analyses, we minimized the biases which can arise through cherry-picking of patients and altering medical treatment on the basis of the test under evaluation (selection and incorporation biases)". This sentence may be more succinctly stated. such as "PCT, IL-6 and IL-8 values were not provided to clinicians to avoid bias"

**This is definitely true, but I'd really like to keep the longer explanation. As a tutor of critical appraisal, I have found the word "bias" is often thrown about as a correct answer, but more knowing it's the code to use than the meaning of it. Additionally, it conforms more strongly to the STROBE checkpoint 9.**

1. As Table 1 states results, it is more appropriate in the results section.

**Fair. This is now a supplementary Table, and Table 1 is within the results.**

The methods reference power calculations suggesting ~400 episodes were required. but only 43 were captured, yet there is no explanation for planned duration or reason for termination of the study.

**Again, reasonable request for the missing information. Added in Methods and Discussion.**

"Results:

1. Data was collected on 65 patients, yet only 31 have had biomarkers taken? Why? Did they refuse collection? Did they present outside of times feasible for biomarker collection? The Discussion references technical and administrative challenges, but maybe expand what you mean? "

**Agreed – discussion paragraph added.**

Final Comment:

- You may consider showing graphically the changes in biomarkers in the 5 SMC patients.

**It is definitely worth considering. Given the very small numbers and the lack of real value of the work in serial measurements arising from this report, as correctly emphasised earlier, adding a graph might well over-egg this part of the pudding again and is probably better left text-based.**

**Competing Interests:** Author of the manuscript

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact [research@f1000.com](mailto:research@f1000.com)

**F1000Research**